Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: After cuts, Pfizer looks to gene therapy, immuno-oncology

    Pfizer Inc. (NYSE:PFE) said it will cut an undisclosed number of R&D jobs at its Cambridge, Mass., and Collegeville, Pa., facilities. Pfizer spokesperson Dean Mastrojohn declined to say which R&D areas would be cut. The…

    Published on 2/25/2015
  • COMPANY NEWS: FDA delays meeting to discuss Remicade biosimilar

    FDA's Arthritis Advisory Committee postponed a meeting that had been scheduled for March 17 to discuss a BLA from Celltrion Inc. (KOSDAQ:068270) for CT-P13, a biosimilar of Remicade infliximab from Johnson & Johnson (…

    Published on 2/25/2015
  • COMPANY NEWS: G-BA backs J&J's Sylvant

    Germany's Federal Joint Committee (G-BA) concluded that Sylvant siltuximab from Johnson & Johnson (NYSE:JNJ) provides added benefit for patients with multicentric Castleman's disease (MCD) who are HIV-negative and human…

    Published on 2/25/2015
  • COMPANY NEWS: Management tracks

    GTx Inc. (NASDAQ:GTXI) hired Robert Wills as executive chairman and chair of its board's Scientific & Development Committee, effective March 2. Wills is retiring as vice president, alliance manager at Johnson & Johnson…

    Published on 2/25/2015
  • COMPANY NEWS: Alkermes discontinues pain candidate, reports earnings

    Alkermes plc (NASDAQ:ALKS) dipped $3 to $70.64 on Tuesday after it discontinued development of pain candidate ALKS 7106 and reported 4Q14 earnings.The company said results from a Phase I trial of ALKS 7106 did not meet …

    Published on 2/24/2015
  • COMPANY NEWS: Management tracks

    Tony Rosenberg, head of M&A and licensing at the Novartis International AG unit of Novartis AG (NYSE:NVS; SIX:NOVN), will retire on Feb. 28. Rosenberg managed the pending asset swap between Novartis and GlaxoSmithKline …

    Published on 2/24/2015
  • COMPANY NEWS: Shire exercises option to acquire Meritage

    Shire plc (LSE:SHP; NASDAQ:SHPG) exercised its option to acquire Meritage Pharma Inc. (San Diego, Calif.) for $70 million up front. Meritage is eligible for $175 million in milestones.The option was triggered by the …

    Published on 2/24/2015
  • COMPANY NEWS: BMS, Rigel in cancer immunotherapy deal

    Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) picked up $0.68 (27%) to $3.23 on Monday after it granted Bristol-Myers Squibb Co. (NYSE:BMY) exclusive, worldwide rights to develop cancer immunotherapies based on Rigel's small…

    Published on 2/23/2015
  • COMPANY NEWS: BMS to acquire Flexus for up to $1.3B

    Bristol-Myers Squibb Co. (NYSE:BMY) will acquire cancer immunotherapy play Flexus Biosciences Inc. (San Carlos, Calif.) for $800 million up front.BMS will receive Flexus' F001287, a preclinical small molecule inhibitor …

    Published on 2/23/2015
  • COMPANY NEWS: Celldex GBM vaccine gets breakthrough designation

    Celldex Therapeutics Inc. (NASDAQ:CLDX) jumped $3.52 (17%) to $24.73 on Monday after FDA granted breakthrough designation to Rintega rindopepimut (CDX-110) to treat adults with EGFR variant III (EGFRvIII)-positive …

    Published on 2/23/2015
  • COMPANY NEWS: Celltrion, Hospira avoid biosimilar traffic jam in U.S.

    With an FDA advisory committee meeting approaching on March 17 for CT-P13 from Celltrion Inc. (KOSDAQ:068270) and Hospira Inc. (NYSE:HSP), the partners' U.S. interests are aligned thanks to an amended deal that gives …

    Published on 2/23/2015
  • COMPANY NEWS: Merck, NGM partner on preclinical compounds

    Merck & Co. Inc. (NYSE:MRK) and NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) entered a five-year research collaboration that gives Merck options to license multiple preclinical candidates from NGM, …

    Published on 2/23/2015
  • COMPANY NEWS: PTC spikes on takeout rumors

    PTC Therapeutics Inc. (NASDAQ:PTCT) rose $9.77 (18%) to $64.96 on Monday on media reports that companies including BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Shire plc (LSE:SHP; NASDAQ:SHPG) are seeking to acquire …

    Published on 2/23/2015
  • COMPANY NEWS: Sosei to acquire Heptares for up to $400M

    Sosei Group Corp. (Tokyo:4565) will acquire Heptares Therapeutics Ltd. (Welwyn Garden City, U.K.) for $180 million up front and up to $220 million in milestones.Sosei will receive Heptares' StaR drug discovery platform …

    Published on 2/23/2015
  • COMPANY NEWS: Valeant to acquire Salix for $14.5B

    Valeant Pharmaceuticals International Inc. (TSX:RVX; NYSE:VRX) will acquire Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) for $158 per share, or $14.5 billion in cash.Salix markets a portfolio of gastrointestinal drugs …

    Published on 2/23/2015
  • COMPANY NEWS: Cerecor licenses KOR antagonist from Lilly

    Eli Lilly and Co. (NYSE:LLY) granted Cerecor Inc. (Baltimore, Md.) exclusive, worldwide rights to LY2456302, a kappa opioid receptor (KOR) (OPRK1) antagonist. Lilly previously developed the candidate to treat co-…

    Published on 2/20/2015
  • COMPANY NEWS: EC approves Chiesi's stem cells for the eye

    The European Commission granted conditional marketing authorization for Holoclar from Chiesi Farmaceutici S.p.A. (Parma, Italy) to treat adults with moderate to severe limbal stem cell deficiency (LSCD) due to physical …

    Published on 2/20/2015
  • COMPANY NEWS: Management tracks

    Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) promoted Lisa Bright to chief commercial and corporate affairs officer. Bright joined Intercept last year as SVP and head of Europe. She previously held several positions at …

    Published on 2/20/2015
  • COMPANY NEWS: Sarissa seeks ouster of Ariad CEO

    Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) rose $0.78 (11%) to $8.05 on Friday after Sarissa Capital Management, the firm led by activist investor Alexander Denner, launched a proxy contest to oust CEO Harvey Berger. …

    Published on 2/20/2015
  • COMPANY NEWS: Genentech's cobimetinib NDA gets Priority Review

    The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said FDA accepted for filing and granted Priority Review to an NDA for MEK inhibitor cobimetinib in combination with the marketed BRAF inhibitor Zelboraf …

    Published on 2/19/2015
  • COMPANY NEWS: Gilead agrees to Sovaldi price cuts in Germany

    Germany's statutory health insurer GKV-Spitzenverband said Gilead Sciences Inc. (NASDAQ:GILD) will offer a 12-week course of Sovaldi sofosbuvir for EUR 43,562 ($49,213), an 11% discount from its German list price of EUR…

    Published on 2/19/2015
  • COMPANY NEWS: Management tracks

    Kymab Ltd. (Cambridge, U.K.) hired Anne Hyland as CFO, effective March 1. Hyland was CFO at BBI Diagnostics Group plc (Cardiff, U.K.) and Vectura Group plc (LSE:VEC).ImmunoCellular Therapeutics Ltd. (NYSE-M:IMUC) hired …

    Published on 2/19/2015
  • COMPANY NEWS: Lead Pharma, Sanofi strike RORgammaT deal

    Lead Pharma Holding B.V. (Nijmegen, the Netherlands) and Sanofi (Euronext:SAN; NYSE:SNY) partnered to develop small molecule inhibitors of RAR-related orphan receptor C thymus-specific isoform (RORgamma2; RORgammaT) to …

    Published on 2/18/2015
  • COMPANY NEWS: Management tracks

    Lycera Corp. (Ann Arbor, Mich.) named Paul Sekhri president, CEO and director, effective immediately. Sekhri was SVP of integrated care at Sanofi (Euronext:SAN; NYSE:SNY).Pharming Group N.V. (Euronext:PHARM) hired Perry…

    Published on 2/18/2015
  • COMPANY NEWS: Eagle lands deal with Teva for EP-3102

    Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) gained $5.12 (24%) to $26.10 after it granted Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) exclusive rights to commercialize EP-3102 in the U.S. Eagle submitted an NDA to FDA …

    Published on 2/17/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993